Collaborative efforts are essential to comprehensively understand the toxicological profiles and devise strategies for mitigating adverse events to optimize the therapeutic potential of RAF and MEK inhibitors in NSCLC treatment. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.